Engineered MAPT Repressors for Tau Protein Aggregation Reduction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapeutic interventions have not been able to effectively curtail or reverse the progression of tauopathies such as Alzheimer's Disease, which are characterized by abnormal tau protein levels and aggregation, leading to cognitive decline and neuronal dysfunction.

Innovation Solution

The use of engineered transcription factor repressors, such as zinc finger proteins (ZFPs), TALEs, and CRISPR/Cas systems, to modulate tau protein expression by binding specifically to the MAPT gene, either alone or in synergistic combinations, delivered via viral vectors like AAV, to reduce tau protein levels and aggregation in the brain.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If engineered transcription factor repressors are used to modulate tau protein expression, then tau protein levels and aggregation are significantly reduced, but the complexity of the therapeutic intervention increases

Engineering Contradiction:

Improvetau protein levelsVSAvoidtherapeutic intervention complexity

Core Design Contradiction:

Quantity of substanceVSDevice complexity

Solution Approach 1:

The patent employs engineered transcription factor repressors (such as zinc finger proteins, TALEs, and CRISPR/Cas systems) as intermediary molecules that specifically bind to the MAPT gene to modulate tau protein expression. These repressors act as mediators between the therapeutic intervention and the target gene, enabling specific reduction of tau protein levels without directly affecting other proteins or pathways.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent utilizes viral vectors (such as AAV) to deliver the genetic material encoding the transcription factor repressors into the brain. This changes the delivery parameter from direct protein administration to genetic material delivery, enabling sustained expression of the repressors and long-term reduction of tau protein levels exceeding 50% and up to 99% in some cases.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If multiple transcription factor repressors are used in synergistic combinations, then tau protein reduction efficacy is enhanced, but the complexity of the treatment increases

Engineering Contradiction:

Improvetau protein reduction efficacyVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent combines multiple transcription factor repressors (such as zinc finger proteins, TALEs, and CRISPR/Cas systems) in synergistic combinations to enhance tau protein reduction efficacy. By merging different repressor systems that target the same or different regions of the MAPT gene, the treatment achieves more reliable and potent reduction of tau protein levels compared to single repressor approaches.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent employs composite therapeutic compositions that include multiple types of transcription factor repressors delivered via viral vectors. These composite treatments integrate different molecular mechanisms (zinc finger binding, TALE binding, CRISPR/Cas cleavage) to work synergistically, creating a more robust and reliable tau reduction effect while managing the complexity through coordinated delivery systems.

Inventive Principle:

Principle #40Composite materials

3Duration of action of stationary object

If viral vectors are used to deliver transcription factor repressors to the brain, then sustained tau protein modulation is achieved, but the risk of off-target effects and immune response increases

Engineering Contradiction:

Improveduration of tau protein modulationVSAvoidoff-target effects and immune response

Core Design Contradiction:

Duration of action of stationary objectVSObject-affected harmful factors

Solution Approach 1:

The patent uses viral vectors to deliver transcription factor repressors specifically to the brain, where tau protein pathology occurs. The repressors are designed to specifically target the MAPT gene sequence, ensuring that the therapeutic action is localized to the intended target. This local specificity reduces off-target effects while maintaining sustained modulation of tau protein levels in the central nervous system.

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The methods achieve significant reduction of tau protein levels and aggregation, leading to amelioration of clinical symptoms and functional improvements in cognitive and neuronal health, with reductions exceeding 50% and up to 99% in some cases.

Implementation Method 1

engineered transcription factor repressors, such as zinc finger proteins (ZFPs), TALEs, and CRISPR/Cas systems, to modulate tau protein expression by binding specifically to the MAPT gene

Methodology Applied

Scientific EffectSpecific binding: